Cargando…

Identification of an Immune Gene-Based Cisplatin Response Model and CD27 as a Therapeutic Target against Cisplatin Resistance for Ovarian Cancer

OBJECTIVE: Evidence demonstrates that the immune microenvironment is extensively associated with chemotherapy response of ovarian cancer (OV). Herein, this study is aimed at establishing a cisplatin response prediction model for OV on the basis of immune genes. METHODS: The expression profiles of ci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Ying, Yang, Na, Li, Gang, Yin, Xiurong, Dong, Lixia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133897/ https://www.ncbi.nlm.nih.gov/pubmed/35647204 http://dx.doi.org/10.1155/2022/4379216

Ejemplares similares

TTK is a potential therapeutic target for cisplatin-resistant ovarian cancer
por: Liu, Yixuan, et al.
Publicado: (2021)

Targeting Heat Shock Protein 27 and Fatty Acid Oxidation Augments Cisplatin Treatment in Cisplatin-Resistant Ovarian Cancer Cell Lines
por: Heiserman, James Patrick, et al.
Publicado: (2023)

Expression of Ferredoxin1 in cisplatin‑resistant ovarian cancer cells confers their resistance against ferroptosis induced by cisplatin
por: Takahashi, Ryosuke, et al.
Publicado: (2023)

Therapeutic Challenges for Cisplatin-Resistant Ovarian Germ Cell Tumors
por: De Giorgi, Ugo, et al.
Publicado: (2019)

Hymenialdisine is Cytotoxic Against Cisplatin-Sensitive but Not Against Cisplatin-Resistant Cell Lines
por: Abdullah, Nada, et al.
Publicado: (2021)

Cisplatin/carboplatin cross-resistance in ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1989)

HSP27 Knockdown Increases Cytoplasmic p21 and Cisplatin Sensitivity in Ovarian Carcinoma Cells
por: Lu, Hao, et al.
Publicado: (2016)

lncRNAs are novel biomarkers for differentiating between cisplatin-resistant and cisplatin-sensitive ovarian cancer
por: Li, Qing, et al.
Publicado: (2018)

Isoalantolactone Suppresses Glycolysis and Resensitizes Cisplatin-Based Chemotherapy in Cisplatin-Resistant Ovarian Cancer Cells
por: Chun, Jaemoo
Publicado: (2023)

Combination therapy with cisplatin and nifedipine induces apoptosis in cisplatin-sensitive and cisplatin-resistant human glioblastoma cells.
por: Kondo, S., et al.
Publicado: (1995)

Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin-resistant ovarian cancer
por: XIE, YA, et al.
Publicado: (2014)

Resensitization of cisplatin resistance ovarian cancer cells to cisplatin through pretreatment with low‐dose fraction radiation
por: Zhao, Lili, et al.
Publicado: (2019)

Apoptosis Induction with Combined Use of Cisplatin and Fisetin in Cisplatin-Resistant Ovarian Cancer Cells (A2780)
por: Jafarzadeh, Samira, et al.
Publicado: (2021)

Potentiation of Cisplatin Cytotoxicity in Resistant Ovarian Cancer SKOV3/Cisplatin Cells by Quercetin Pre-Treatment
por: Hasan, Aseel Ali, et al.
Publicado: (2023)

Downstream Effectors of ILK in Cisplatin-Resistant Ovarian Cancer
por: Reyes-González, Jeyshka M., et al.
Publicado: (2020)

Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer
por: Schweer, David, et al.
Publicado: (2021)

Anlotinib Exerts Inhibitory Effects against Cisplatin-Resistant Ovarian Cancer In Vitro and In Vivo
por: Ji, Yurou, et al.
Publicado: (2022)

Dacomitinib improves chemosensitivity of cisplatin-resistant human ovarian cancer cells
por: Xu, Lei, et al.
Publicado: (2021)

Identification of solamargine as a cisplatin sensitizer through phenotypical screening in cisplatin-resistant NSCLC organoids
por: Han, Yi, et al.
Publicado: (2022)

Proteasome Inhibitor YSY01A Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells
por: Huang, Wei, et al.
Publicado: (2016)

Deregulation of Exo70 Facilitates Innate and Acquired Cisplatin Resistance in Epithelial Ovarian Cancer by Promoting Cisplatin Efflux
por: Zhao, Yujie, et al.
Publicado: (2021)

Purvalanol A induces apoptosis and reverses cisplatin resistance in ovarian cancer
por: Zhang, Xiaoyi, et al.
Publicado: (2022)

Insight into Cisplatin-Resistance Signaling of W1 Ovarian Cancer Cells Emerges mTOR and HSP27 as Targets for Sensitization Strategies
por: Wantoch von Rekowski, Kathleen, et al.
Publicado: (2020)

Cisplatin and Doxorubicin Induce Distinct Mechanisms of Ovarian Follicle Loss; Imatinib Provides Selective Protection Only against Cisplatin
por: Morgan, Stephanie, et al.
Publicado: (2013)

Epigenetic modification of α-N-acetylgalactosaminidase enhances cisplatin resistance in ovarian cancer
por: Ha, Ye-Na, et al.
Publicado: (2018)

Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinoma
por: McCabe, K E, et al.
Publicado: (2014)

Filtering of the Gene Signature as the Predictors of Cisplatin-Resistance in Ovarian Cancer
por: Ataei, Atousa, et al.
Publicado: (2021)

Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer
por: Huang, Linjuan, et al.
Publicado: (2023)

Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes
por: Teng, P-N, et al.
Publicado: (2014)

Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cells.
por: Zaffaroni, N., et al.
Publicado: (1998)

Cisplatin induces stemness in ovarian cancer
por: Wiechert, Andrew, et al.
Publicado: (2016)

Molecular mechanism of CD163(+) tumor-associated macrophage (TAM)-derived exosome-induced cisplatin resistance in ovarian cancer ascites
por: Zhang, Xiaohui, et al.
Publicado: (2022)

Cisplatin-resistant HepG2 cell-derived exosomes transfer cisplatin resistance to cisplatin-sensitive cells in HCC
por: Tang, Zuxiong, et al.
Publicado: (2021)

Inhibition of 6-phosphogluconate Dehydrogenase Reverses Cisplatin Resistance in Ovarian and Lung Cancer
por: Zheng, Wujian, et al.
Publicado: (2017)

Identification of genes contributing to cisplatin resistance in osteosarcoma cells
por: Xie, Mingzhong, et al.
Publicado: (2022)

Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance
por: Leung, E L, et al.
Publicado: (2008)

Cucurbit [7] uril encapsulated cisplatin overcomes resistance to cisplatin induced by Rab25 overexpression in an intraperitoneal ovarian cancer model
por: Gomez-Roman, Natividad, et al.
Publicado: (2015)

Paclitaxel and SN‐38 Overcome Cisplatin Resistance of Ovarian Cancer Cell Lines by Down‐regulating the Influx and Efflux System of Cisplatin
por: Komuro, Yuuki, et al.
Publicado: (2001)

Efficacy of HDAC Inhibitors Belinostat and Panobinostat against Cisplatin-Sensitive and Cisplatin-Resistant Testicular Germ Cell Tumors
por: Lobo, João, et al.
Publicado: (2020)

eIF3a improve cisplatin sensitivity in ovarian cancer by regulating XPC and p27(Kip1) translation
por: Zhang, Yu, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_jpgv812g8ltolmh2adks08nru1